Please complete the human subjects section of the Research & Related Other Project Information form prior to completing this form.

The following items are taken from the Research & Related Other Project Information form and displayed here for your reference. Any changes to these fields must be made on the Research & Related Other Project Information form and may impact the data items you are required to complete on this form.

### Are Human Subjects Involved?

- [ ] Yes
- [ ] No

### Is the Project Exempt from Federal regulations?

- [ ] Yes
- [ ] No

Exemption number: [ ] 1  [ ] 2  [ ] 3  [ ] 4  [ ] 5  [ ] 6  [ ] 7  [ ] 8

**If No to Human Subjects**

Does the proposed research involve human specimens and/or data?

- [ ] Yes
- [ ] No

If Yes, provide an explanation of why the application does not involve human subjects research.

**If Yes to Human Subjects**

Add a record for each proposed Human Subject Study by selecting ‘Add New Study’ or ‘Add New Delayed Onset Study’ as appropriate. Delayed onset studies are those for which there is no well-defined plan for human subject involvement at the time of submission, per agency policies on Delayed Onset Studies. For delayed onset studies, you will provide the study name and a justification for omission of human subjects study information.

### Other Requested Information

Check Application Guide and opportunity instructions to determine if attachment is needed.

**Study Record(s)**

Attach human subject study records using unique filenames.

1) Please attach Human Subject Study 1

### Delayed Onset Study(ies)

**Cannot add a Delayed Onset Study if you answer No to human subjects question on R&R Other Project Information form.**

Multi-ple delayed onset studies can be grouped in a single record.

<table>
<thead>
<tr>
<th>Study Title</th>
<th>Anticipated Clinical Trial?</th>
<th>Justification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Required and system enforced for each delayed onset study. Up to 600 characters. Study title must be unique within the application. First 150 characters of title will show in application bookmark.</td>
<td>[ ]</td>
<td></td>
</tr>
</tbody>
</table>

If Anticipated Clinical Trial box is checked, FOA must allow clinical trials. When multiple studies are included in the same delayed onset record, select Yes if it is anticipated that any study will be a clinical trial.

Required and system enforced for each delayed onset study. In addition to justification, must include information regarding how the study will comply with the NIH single Institutional Review Board (sIRB) policy prior to initiating any multi-site study, as well as, a plan for the dissemination of NIH-funded clinical trial information.
Section 1 - Basic Information

1.1. * Study Title (each study title must be unique)
- Required and system enforced. Up to 600 characters. Study title must be unique within the application. First 150 characters of title will show in application bookmark.

1.2. * Is this Study Exempt from Federal Regulations?
   - Yes
   - No

1.3. Exemption Number
   - 1
   - 2
   - 3
   - 4
   - 5
   - 6
   - 7
   - 8

1.4. * Clinical Trial Questionnaire
   - Answers to questionnaire required and system enforced.
   - If Study Exempt is Yes, must provide exemption number.

   If the answers to all four questions below are yes, this study meets the definition of a Clinical Trial.

   1.4.a. Does the study involve human participants?
   - Yes
   - No

   1.4.b. Are the participants prospectively assigned to an intervention?
   - Yes
   - No

   1.4.c. Is the study designed to evaluate the effect of the intervention on the participants?
   - Yes
   - No

   1.4.d. Is the effect that will be evaluated a health-related, biomedical, or behavioral outcome?
   - Yes
   - No

1.5. Provide the ClinicalTrials.gov Identifier (e.g., NCT87654321) for this trial, if applicable

Section 2 - Study Population Characteristics

2.1. Conditions or Focus of Study
   - Required and system enforced unless study is exemption 4. Up to 20 conditions at 255 characters each.

2.2. Eligibility Criteria
   - Required and system enforced unless study is exemption 4 or otherwise noted in opportunity.

2.3. Age Limits
   - Minimum Age
   - Maximum Age

2.4. Inclusion of Women, Minorities, and Children
   - Inclusion Enrollment Report(s)

2.5. Recruitment and Retention Plan
   - Recruitment Status
   - Study Timeline

2.6. Recruitment Status
   - Recruitment Status

2.7. Study Timeline
   - Enrollment of First Subject

2.8. Enrollment of First Subject
   - Enrollment of First Subject

* Fellowship (F) and Career Development (K) applications to FOAs that do not allow clinical trials cannot propose independent clinical trial studies led by applicant PD/PI. However, proposing studies under the leadership of a sponsor/mentor that allows for clinical trials research experience is encouraged. Such studies must include HS information, but will receive a system error if information is included in CT study fields in sections 4 or 5 of form.
### Inclusion Enrollment Report

1. * Using an Existing Dataset or Resource
   - Yes
   - No
   ```
   Answer required and system enforced.
   ```

2. * Enrollment Location Type
   - Domestic
   - Foreign
   ```
   Answer required and system enforced. Do not mix domestic and foreign enrollment data on the same inclusion enrollment report.
   ```

3. Enrollment Country(ies)
   
   Multi-select from list of countries.

4. Enrollment Location(s)

5. Comments

   Up to 500 characters.

---

#### Planned

Planned enrollment information is required and system enforced when answer to "Using an Existing Dataset or Resource" question is No. System enforcement relaxed if Comment is provided.

<table>
<thead>
<tr>
<th>Racial Categories</th>
<th>Ethnic Categories</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Not Hispanic or Latino</td>
<td>Hispanic or Latino</td>
<td>Total</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td>American Indian/Alaska Native</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Native Hawaiian or Other Pacific Islander</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black or African American</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>More than One Race</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Racial Categories</td>
<td>Not Hispanic or Latino</td>
<td>Hispanic or Latino</td>
<td>Unknown/Not Reported Ethnicity</td>
<td>Total</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>------------------------</td>
<td>-------------------</td>
<td>-------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>Male</td>
<td>Unknown/Not Reported</td>
<td>Female</td>
</tr>
<tr>
<td>American Indian/Alaska Native</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Asian</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Native Hawaiian or Other Pacific Islander</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Black or African American</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>White</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>More than One Race</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Unknown or Not Reported</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Report 1 of 1
Section 3 - Protection and Monitoring Plans

3.1. Protection of Human Subjects

3.2. Is this a multi-site study that will use the same protocol to conduct non-exempt human subjects research at more than one domestic site?

- Yes
- No
- N/A

3.3. Data and Safety Monitoring Plan

3.4. Will a Data and Safety Monitoring Board be appointed for this study?

- Yes
- No

3.5. Overall Structure of the Study Team

Section 4 - Protocol Synopsis

4.1. Brief Summary

4.2. Study Design

4.2.a. Narrative Study Description

4.2.b. Primary Purpose

4.2.c. Interventions

- Up to 20 Interventions allowed.

<table>
<thead>
<tr>
<th>Intervention Type</th>
<th>Dropdown list</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td>Up to 200 characters.</td>
</tr>
<tr>
<td>Description</td>
<td>Up to 1,000 characters.</td>
</tr>
</tbody>
</table>

4.2.d. Study Phase

- Dropdown list

- Is this an NIH-defined Phase III clinical trial?

- Yes
- No

4.2.e. Intervention Model

- Dropdown list

4.2.f. Masking

- Yes
- No

- Participant
- Care Provider
- Investigator
- Outcomes Assessor

If Masking is Yes, you must select at least 1 of the Participant/Care Provider/Investigator/Outcomes Assessor check boxes.
### 4.2.g. Allocation

Dropdown list

- Randomized
- Non-randomized

### 4.3. Outcome Measures

At least one Outcome Measure required and system enforced for CT studies unless otherwise noted in opportunity. Up to 50 Outcome Measures allowed.

<table>
<thead>
<tr>
<th>Name</th>
<th>Up to 255 characters.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type</td>
<td>Dropdown list</td>
</tr>
<tr>
<td></td>
<td>Primary</td>
</tr>
<tr>
<td></td>
<td>Secondary</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>Time Frame</td>
<td>Up to 255 characters.</td>
</tr>
<tr>
<td>Brief Description</td>
<td>Up to 999 characters.</td>
</tr>
</tbody>
</table>

### 4.4. Statistical Design and Power

Required and system enforced for CT study unless otherwise noted in opportunity.

### 4.5. Subject Participation Duration

Required and system enforced for CT study unless otherwise noted in opportunity.

### 4.6. Will the study use an FDA-regulated intervention?

- [ ] Yes
- [ ] No

Answer required and system enforced for CT study unless otherwise noted in opportunity.

4.6.a. If yes, describe the availability of Investigational Product (IP) and Investigational New Drug (IND)/Investigational Device Exemption (IDE) status

Required and system enforced if Yes.

### 4.7. Dissemination Plan

Required and system enforced for CT study. Generally one Dissemination Plan per application is sufficient. Can attach same plan in multiple studies.